THE European Medicines
Agency’s (EMA’s)
Pharmacovigilance Risk Assessment
Committee (PRAC) has reviewed
diabetes drugs SGLT2 inhibitors and
warned healthcare professionals
to exercise caution in patients with
risk factors, to minimise the risk of
diabetic ketoacidosis.
The three SGLT2 inhibitors
authorised in the EU are
canagliflozin, dapagliflozin and
empagliflozin.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Feb 16
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.